ArticleTherapeutic advances in infectious disease
Re-estimation of the burden of serious fungal diseases in Uganda.
Article in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Economic burden of chronic pulmonary aspergillosis in Uganda: a cost-of-illness analysis.IJID regions · 2026Article
- The Dynamiker cryptococcal antigen lateral flow assay is an accurate, rapid and cost effective test comparable to culture for detection of cryptococcal meningitis.Journal of medical microbiology · 2026Article
- Burden and Challenges in the Diagnosis and Treatment of Histoplasmosis Among Persons With Advanced HIV Disease in Uganda, 2025.Open forum infectious diseases · 2026Article
- Risk factors for cryptococcal infection among people with HIV receiving care at a referral hospital in Uganda: a nested case-control study.BMC infectious diseases · 2026Article
- Secondary infections following tuberculosis: epidemiology, pathogenesis and clinical implications.Breathe (Sheffield, England) · 2026Review
- Economic burden of recurrent vulvovaginal candidiasis in Uganda: a cost-of-illness analysis.IJID regions · 2025Article
- Baseline knowledge on chronic pulmonary aspergillosis and tuberculosis among health care workers involved in tuberculosis care in Uganda.IJID regions · 2025Article
- Increasing postgraduate medical mycology research dissertations at Uganda's higher institution of learning.IJID regions · 2025Article
- Experiences, challenges, gaps, and strategies for counselling persons presenting with advanced HIV-associated meningitis in Uganda.AIDS research and therapy · 2025Article
- Article
- Primary treatment of chronic pulmonary aspergillosis with weekly liposomal amphotericin B: A case report from Uganda.Medical mycology case reports · 2024Article
- In vitro antifungal activities of medicinal plants used for treatment of candidiasis in Pader district, Northern Uganda.Tropical medicine and health · 2024Article
- Lack of Candida africana in Ugandan pregnant women: results from a pilot study using MALDI-ToF.BMC research notes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It is of utmost importance to monitor any change in the epidemiology of fungal diseases that may arise from a change in the number of the at-risk population or the availability of local data. Objective: We sought to update the 2015 publication on the incidence and prevalence of serious fungal diseases in Uganda. Methods: Using the Leading International Fungal Education methodology, we reviewed published data on fungal diseases and drivers of fungal diseases in Uganda. Regional or global data were used where there were no Ugandan data. Results: With a population of ~45 million, we estimate the annual burden of serious fungal diseases at 4,099,357 cases (about 9%). We estimated the burden of candidiasis as follows: recurrent Conclusion: Serious fungal diseases affect nearly 9% of Ugandans every year. Tuberculosis and HIV remain the most important predisposition to acute fungal infection necessitating accelerated preventive, diagnostic, and therapeutic interventions for the management of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.